Aldeyra Therapeutics Inc.

NASDAQ: ALDX · Real-Time Price · USD
5.33
0.03 (0.57%)
At close: Aug 15, 2025, 3:47 PM

Aldeyra Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
244.53K 244.53K 244.53K 392.62K 392.62K 392.62K 392.62K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
308.44K 307.79K 307.51K 251.72K 253.73K 256.44K 262.78K 196.31K 196.62K 196.29K 192.06K 253.33K 256.38K 192.36K 197.49K 136.22K 67.86K 67.86K
Gross Profit
-63.92K -63.27K -62.99K -251.72K -253.73K -256.44K -262.78K -196.31K -196.62K -196.29K -192.06K -253.33K -256.38K -259.06K -264.18K -202.91K -134.56K -67.86K
Operating Income
-10,168.8B -61.15M -60.12M -49.64M -43.05M -35.38M -42.79M -50.39M -55.63M -63M -62.68M -64.39M -65.04M -61.87M -56.22M -52.1M -45.05M -37.61M
Interest Income
4.6M 5.36M 6.19M 6.81M 7.21M 7.45M 7.32M 6.72M 5.47M 3.93M 2.35M 1.16M 567.7K 262.98K 185.36K 127.93K 73.84K 105.89K
Pretax Income
-9,767.4B -57.7M -55.85M -44.8M -37.87M -30.01M -37.54M -45.69M -52.06M -60.85M -62.02M -64.88M -66.12M -63.27M -57.78M -53.79M -46.87M -39.45M
Net Income
-9,767.4B -57.7M -55.85M -44.8M -37.87M -30.01M -36.85M -44.99M -51.13M -59.99M -62.16M -65.02M -66.49M -63.58M -57.78M -53.31M -46.39M -38.98M
Selling & General & Admin
1,663.5B 11.56M 11.83M 11.62M 10.51M 10.91M 13.27M 16.27M 16.93M 16.69M 15.37M 13.2M 12.5M 12.43M 11.28M 11.23M 10.94M 10.09M
Research & Development
8,505.3B 49.47M 48.23M 37.89M 32.41M 24.41M 29.46M 34.12M 38.7M 46.31M 47.31M 51.19M 52.54M 49.44M 44.94M 39.12M 32.36M 25.77M
Other Expenses
-10,168.7B 61.46K -492 66.29K 65.29K 65.29K 65.78K -1K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
53.25M 61.09M 60.06M 49.58M 42.99M 35.38M 42.79M 50.39M 55.63M 63M 62.68M 64.39M 65.04M 61.87M 56.22M 50.35M 43.3M 35.86M
Interest Expense
1.9M 1.91M 1.93M 1.97M 2.03M 2.08M 2.07M 2.02M 1.9M 1.78M 1.69M 1.65M 1.64M 1.67M 1.74M 1.82M 1.89M 1.95M
Selling & Marketing Expenses
n/a -61.63K -61.63K -128.1K -128.1K -66.47K -66.47K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
53.31M 61.15M 60.12M 49.64M 43.05M 35.38M 42.79M 50.39M 55.63M 63M 62.68M 64.39M 65.04M 61.87M 56.22M 50.35M 43.3M 35.86M
Income Tax Expense
3.00 3.00 3.00 n/a n/a n/a -696K -696K -927K -860.98K 139.6K 139.6K 429.91K 403.56K 122.73K -356.27K -410.36K -378.31K
Shares Outstanding (Basic)
60.05M 59.89M 59.48M 59.53M 59.41M 59.41M 59.2M 58.99M 58.79M 58.79M 58.56M 58.46M 58.3M 58.3M 58.02M 58.02M 54.28M 45.63M
Shares Outstanding (Diluted)
60.05M 59.89M 59.48M 59.53M 59.41M 59.41M 59.2M 58.99M 58.79M 58.79M 58.56M 58.46M 58.3M 58.3M 58.02M 58.02M 54.28M 45.63M
EPS (Basic)
-0.85 -0.97 -0.94 -0.75 -0.64 -0.51 -0.62 -0.76 -0.86 -1.02 -1.06 -1.11 -1.14 -1.11 -1.07 -1.05 -1.01 -0.98
EPS (Diluted)
-0.85 -0.97 -0.94 -0.75 -0.64 -0.51 -0.62 -0.76 -0.86 -1.02 -1.06 -1.11 -1.14 -1.11 -1.07 -1.05 -1.01 -0.98
EBITDA
-10,168.8B -55.54M -53.68M -42.57M -35.59M -27.67M -35.21M -43.41M -49.9M -58.81M -60.07M -62.98M -64.22M -61.35M -55.77M -51.77M -44.77M -37.29M
EBIT
-48.71M -55.79M -53.93M -42.83M -35.84M -27.93M -35.47M -43.67M -50.16M -59.07M -60.33M -63.23M -64.48M -61.61M -56.03M -51.97M -44.98M -37.51M
Depreciation & Amortization
250.55K 249.9K 249.62K 251.72K 253.73K 256.44K 262.78K 262.95K 263.26K 262.94K 258.71K 253.33K 256.38K 259.06K 264.18K 40.91K 45.68K 51.63K